NCT03082937View on ClinicalTrials.gov

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 8, 2017

Study Completion Date

March 8, 2017

Conditions
Orphan Cholestatic Liver DiseasesProgressive Familial Intrahepatic CholestasisAlagille SyndromePrimary Biliary Cirrhosis
Interventions
DRUG

3 mg [14C]-A4250 capsule

Each subject will receive a single administration of 3 mg \[14C\]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

Sponsors

Lead Sponsor

Albireo
All Listed Sponsors
lead

Albireo

INDUSTRY

NCT03082937 - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects | Biotech Hunter | Biotech Hunter